#1 Clinical Trials Search in Europe

Omeprazole

Omeprazole, a widely used proton pump inhibitor, has been the subject of numerous clinical trials to evaluate its efficacy and safety in treating various gastrointestinal conditions. This article summarizes key findings from clinical studies investigating omeprazole’s use in different formulations, dosages, and patient populations. We’ll explore its effects on gastric acid suppression, bioequivalence with other medications, and its role in managing conditions such as eosinophilic esophagitis and post-bariatric surgery care.

Table of Contents

What is Omeprazole?

Omeprazole is a medication that belongs to a class of drugs called proton pump inhibitors (PPIs). It is widely used to treat various conditions related to the stomach and esophagus[1]. Omeprazole works by reducing the amount of acid produced in the stomach, which can help alleviate symptoms and promote healing in certain digestive disorders[2].

How Omeprazole Works

Omeprazole functions by blocking an enzyme in the stomach called the proton pump. This enzyme is responsible for producing stomach acid. By inhibiting this enzyme, omeprazole effectively reduces the amount of acid in the stomach. This mechanism of action helps to relieve symptoms caused by excess stomach acid and allows damaged tissues in the digestive tract to heal[3].

Conditions Treated with Omeprazole

Omeprazole is used to treat several conditions affecting the digestive system, including:

  • Gastroesophageal Reflux Disease (GERD): A condition where stomach acid frequently flows back into the esophagus, causing heartburn and potential damage to the esophagus[4].
  • Stomach Ulcers: Open sores that develop on the lining of the stomach[4].
  • Duodenal Ulcers: Ulcers that occur in the first part of the small intestine (duodenum)[3].
  • Helicobacter Pylori Infection: A bacterial infection that can cause ulcers and is often treated with a combination of omeprazole and antibiotics[1].
  • Dyspepsia: A term used to describe indigestion or upper abdominal discomfort[2].
  • Eosinophilic Esophagitis (EoE): An allergic condition of the esophagus that can cause difficulty swallowing and other symptoms[5].

Dosage Forms and Brand Names

Omeprazole is available in various forms and under different brand names:

  • Delayed-Release (DR) Capsules: These capsules are designed to release the medication in the small intestine rather than the stomach[6].
  • Tablets: Regular tablets that can be swallowed whole[6].
  • Immediate-Release Formulations: These forms release the medication more quickly in the body[4].

Common brand names for omeprazole include:

  • Prilosec[7]
  • Prilosec OTC (over-the-counter version)[7]
  • Losec[4]
  • Zegerid (a combination of omeprazole and sodium bicarbonate)[7]

Potential Side Effects

While omeprazole is generally well-tolerated, some people may experience side effects. Common side effects may include:

  • Headache
  • Nausea
  • Diarrhea
  • Abdominal pain
  • Flatulence (gas)

It’s important to note that serious side effects are rare but can occur. If you experience any unusual or severe symptoms while taking omeprazole, contact your healthcare provider immediately[8].

Drug Interactions

Omeprazole can interact with other medications, potentially affecting how they work in the body. Some notable interactions include:

  • Clopidogrel: Omeprazole may reduce the effectiveness of this blood-thinning medication.
  • Certain HIV medications: Omeprazole might affect the absorption of some antiretroviral drugs.
  • Iron supplements: Omeprazole can reduce iron absorption in the body[1].

Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions[9].

Special Considerations

When using omeprazole, keep in mind the following:

  • Long-term use: Prolonged use of omeprazole may lead to decreased absorption of certain nutrients, such as vitamin B12 and magnesium. Your doctor may recommend periodic blood tests to monitor these levels[1].
  • Pregnancy and breastfeeding: If you are pregnant, planning to become pregnant, or breastfeeding, consult your healthcare provider before using omeprazole.
  • Children: Omeprazole can be used in children, but dosages may differ. Always follow your pediatrician’s instructions[5].
  • Elderly patients: Older adults may be more sensitive to the effects of omeprazole and may require dose adjustments.

Remember, while this information provides a general overview of omeprazole, it’s essential to consult with your healthcare provider for personalized advice and treatment recommendations based on your specific medical condition and needs.

Aspect Details
Common Formulations Delayed-release capsules, tablets (e.g., Prilosec OTC)
Dosages Studied 20 mg, 40 mg
Primary Uses in Trials Gastric acid suppression, treatment of GERD, eosinophilic esophagitis
Comparison Studies Bioequivalence with other brands, comparison with other PPIs (e.g., lansoprazole)
Effectiveness Measures Gastric pH levels, integrated gastric acidity, histological response
Special Populations Pediatric patients, bariatric surgery patients
Safety Considerations Generally well-tolerated, adverse events monitored in trials
Pharmacokinetic Parameters AUC, Cmax, time to reach maximum concentration

FAQ

  • What is omeprazole used for in clinical trials? Omeprazole is primarily used in clinical trials to study its effectiveness in suppressing gastric acid production. It's tested for treating conditions like gastroesophageal reflux disease (GERD), stomach ulcers, and eosinophilic esophagitis. Some trials also compare its bioequivalence with other similar medications or different formulations of omeprazole itself.
  • How does omeprazole compare to other similar medications? Clinical trials have compared omeprazole to other proton pump inhibitors like lansoprazole (Prevacid). For example, one study compared Prilosec OTC (omeprazole) to Prevacid for gastric acid suppression. These comparisons help determine the relative effectiveness of different medications in the same class.
  • What are some common dosages of omeprazole used in clinical trials? Clinical trials have used various dosages of omeprazole, including 20 mg and 40 mg formulations. For instance, some studies used Prilosec OTC 20 mg tablets, while others tested omeprazole magnesium 20.6 mg or omeprazole 40 mg delayed-release capsules. The dosage often depends on the specific condition being treated and the purpose of the study.
  • How is omeprazole's effectiveness measured in clinical trials? Omeprazole's effectiveness is often measured by its ability to suppress gastric acid. Common measurements include the mean percent time that gastric pH is above 4.0, integrated gastric acidity, and histological response in conditions like eosinophilic esophagitis. Researchers also assess pharmacokinetic parameters such as maximum concentration (Cmax) and area under the curve (AUC) to evaluate bioequivalence.
  • Are there any special considerations for omeprazole use in certain patient populations? Yes, some clinical trials have focused on specific patient populations. For example, one study investigated the bioavailability of omeprazole in patients before and after bariatric surgery. Another trial examined its effectiveness in pediatric patients with eosinophilic esophagitis. These studies help determine how omeprazole's effectiveness may vary in different patient groups or under specific medical conditions.

Ongoing Clinical Trials on Omeprazole

  • Study on Omeprazole and Cow’s Milk-Free Diet for Treating Gastroesophageal Reflux Disease in Infants Under 1 Year

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on the Effectiveness of Budesonide and Omeprazole for Treating Crohn’s Disease in the Esophagus, Stomach, or Duodenum in Children

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Poland

  • Long-Term Safety and Efficacy Study of Botaretigene Sparoparvovec for Patients with X-Linked Retinitis Pigmentosa

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark France Italy The Netherlands Spain

Glossary

  • Bioequivalence: The property of two drug products having the same active ingredient, dosage form, strength, and route of administration to show comparable bioavailability and produce the same therapeutic effect when administered to patients under similar conditions.
  • Proton Pump Inhibitor (PPI): A class of medications that reduce stomach acid production by blocking the enzyme in the wall of the stomach that produces acid. Omeprazole is an example of a PPI.
  • Gastroesophageal Reflux Disease (GERD): A digestive disorder that occurs when stomach acid frequently flows back into the esophagus, causing symptoms such as heartburn and difficulty swallowing.
  • Eosinophilic Esophagitis (EoE): A chronic immune system disease characterized by a buildup of white blood cells (eosinophils) in the lining of the esophagus, causing inflammation and difficulty swallowing.
  • Delayed Release (DR): A formulation of medication designed to release the active ingredient later after ingestion, often used to protect the drug from stomach acid or to reduce side effects.
  • Area Under the Curve (AUC): A pharmacokinetic parameter that represents the total drug exposure over time, used to assess bioequivalence and drug absorption.
  • Maximum Concentration (Cmax): The highest concentration of a drug in the blood, plasma, or serum after administration, used to evaluate the rate and extent of drug absorption.
  • Histological Response: Changes in tissue structure observed under a microscope following treatment, used to assess the effectiveness of medications in conditions like eosinophilic esophagitis.
  • Transnasal Endoscopy (TNE): A procedure where a thin, flexible tube with a camera is inserted through the nose to examine the upper digestive tract, often used as an alternative to traditional endoscopy.
  • Bariatric Surgery: Weight loss surgery that involves making changes to the digestive system to help patients lose weight and improve obesity-related health problems.

References

  1. https://clinicaltrials.gov/study/NCT03146325
  2. https://clinicaltrials.gov/study/NCT04069286
  3. https://clinicaltrials.gov/study/NCT00971581
  4. https://clinicaltrials.gov/study/NCT02710994
  5. https://clinicaltrials.gov/study/NCT04149470
  6. https://clinicaltrials.gov/study/NCT01045434
  7. https://clinicaltrials.gov/study/NCT00808769
  8. https://clinicaltrials.gov/study/NCT05067439
  9. https://clinicaltrials.gov/study/NCT01415128